Neuropsychopharmacology meetings & conferences

14th International Congress on Schizophrenia Research

Sunday 21 through Thursday 25 April 2013 Orlando, Florida. Satellite Meetings will be held Saturday 20 and Sunday 21 April 2013.

1st International Conference on Cultural Psychiatry in Mediterranean Countries

November 5-7, 2012 Tel Aviv, Israel

The 1st International Conference on Cultural Psychiatry in Mediterranean Countries is a highly anticipated and ambitious event that seeks to deal with novel issues appearing in a world of open frontiers, new opportunities and international upheaval and conflicts, particularly relevant in light of recent events in the region.

Identity is an evolving concept, where group boundaries have become blurred. Mental health professionals will be given the opportunity to participate in stimulating and fruitful discussions on a great variety of issues such as clinical aspects of acculturative stress, neuropsychopharmacology and integrative treatment methods.

The conference, to be held 5-7 November 2012, is aimed at leading psychiatrists, psychologists, social workers, social anthropologists, students and anyone with a specialized interest in the rapidly evolving area of transcultural psychiatry.

Preliminary List of Topics

Mood, anxiety and psychotic disorders related to migration
Cultural neuropsychopharmacology
Suicide and cultural transition
Trauma and migration
Religiosity and spirituality
Stigma and Culture
Cultural transition

Kenes International
Kenes Group Building
2 Hayarden St.
Airport City, Lod 70151
Israel
Tel: +972 3 9727405
Fax: + 972 72 2447271
E-mail: wpa-tps@kenes-events.com

51st Annual Meeting of the American College of Neuropsychopharmacology

December 2-6, 2012 Hollywood, Florida

The ACNP Annual Meeting is open only to members and their invited guests.

The Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psycotropic drugs.

The Annual Meeting provides an opportunity to:

Attend an outstanding scientific program in clinical and basic research on brain behavior-drug interactions
Learn about the most recent and often unpublished advances in psychopharmacology
Meet and interact with internationally distinguished researchers and scientists

International Society for the Study of Trauma and Dissociation 2012 Annual Conference

October 20-22, 2012 Long Beach, California

ISSTD will explore this theme of Integrating Science and Practice: Moving forward together in the field of Trauma and Dissociation. Come be a part of the conference. Submit your proposals to explore this idea together.

Conference objectives

1. Learn about the most recent research on Complex Posttraumatic Disorders, Dissociative Disorders, Developmental Trauma Disorder, and their relationships with one another.

2. Describe the central role of dissociation in posttraumatic reactions and disorders.

3. Increase knowledge about the assessment and treatment of trauma and dissociation in children, adolescents, and adults.

4. Identify the subjective symptoms and objective signs of dissociation, learn how best to understand these phenomena, and how to conduct methodologically sound research on dissociation.

5. Develop an appreciation for, and engage in dialogue about, the roles and forms of dissociation in different cultures and geographic regions.

6. Learn about the diagnosis, treatment, and developmental needs of children and adolescents who have been repeatedly traumatized, abused, and/or neglected.

7. Learn about assessment, diagnosis, theories, and treatment approaches for adults with complex posttraumatic symptoms and disorders

8. Describe the relationships among trauma-driven symptoms, posttraumatic disorders, and other common mental disorders (especially anxiety and depressive disorders).

9. Identify the core clinical areas of competence for clinicians who work with complex trauma and dissociation.

10. Learn new treatment techniques and pharmacological interventions for complex trauma and dissociation.

11. Identify ways that treatment can go wrong for patients with complex posttraumatic and dissociative disorders, learn how to avoid these pitfalls, and learn how to resolve these impasses should they occur.

12. Describe and successfully manage the complex interactional dynamics (transference and countertransference reactions) that routinely characterize the therapy of persons with complex trauma-related disorders.

Questions?

International Society for the Study of Trauma and Dissociation
8400 Westpark Drive, 2nd Floor
McLean, VA 22102 USA
Phone: 703-610-9037
Fax: 703-610-0234

12th International Forum on Mood and Anxiety Disorders

November 7-9 2012 Barcelona, Spain

The most useful feature about IFMAD meetings is that current clinical hot topics and new data are presented in a balanced format, adequately dissected and discussed in a collegiate atmosphere, and digested over dinner.

The meetings are always enjoyable and informative and along with the usual updates on new treatments in other areas this year’s IFMAD will be an efficient way of catching up with the latest developments.

This year topics that will be addressed include educational strategies to prevent suicide, the place of antidepressants in bipolar depression, new approaches in treating alcohol abuse, improving placebo control groups and a core focus will be on the new antidepressants on the horizon.

The list of preliminary topics for IFMAD 2012:

How soon can nonresponse be declared ?
Mistakes in DSM-V bipolar definitions
Do antidepressants have a place in bipolar depression
Are 2 antidepressants better than one ?
Are there too many anxiety disorders ?
Is worry too common to be diagnostic of GAD?
New antidepressants on the horizon
A new approach to treating alcohol abuse
Improving placebo control groups
Celebrities and borderline personality
Do suicide warnings help or harm?
Can educational strategies prevent suicide?
Raising the dose in non-responders – is it useful?
Efficacy of psychiatric drugs in prospective

Secretariat - Publicreations
74, Bd d’Italie, Monte Carlo - MC98000 (Monaco)
Ph.: +377 9797 3555 - Fax: +377 9797 3550
Email:ifmad@publicreations.com

Cognitive Enhancers: 22nd Neuropharmacology Conference

Official Satellite to the 2012 Meeting of the Society for Neuroscience

11-12 October 2012 New Orleans, Louisiana

Cognitive enhancement has become a subject of considerable research and, both in neuroscience and society at large, growing controversy. This satellite meeting will survey progress in the field from attempts to facilitate the substrates of memory and cognition in animal models to clinical studies targeted at major psychiatric disorders. Attendees will accordingly have a first-hand opportunity to learn about the broad spectrum of enhancement research ranging from epigenetics through synaptic plasticity and brain networks to behavior. Individual sessions include both cutting edge work on currently marketed drugs and experiments using novel, mechanism-based compounds. The program will therefore be of interest to those interested in present and future therapeutic prospects for autism, age-related cognitive decline, addiction, and depression. It also directly addresses the possibility of enhancement in normal subjects, a contentious issue that affects much of the neuroscience community.

Topics List

Enhancing brain substrates of cognition:
Plasticity and memory
Cortical systems
Enhancement as a treatment for cognitive disorders:
Aging
Spine dysfunction
Experience and epigenetics
Affective disorders
Schizophrenia
Autism spectrum disorders

For queries, please contact:

Richard Hart
Email: r.hart@elsevier.com
 

International Conference on Clinical Practice in Alzheimer Disease

Thursday, November 8, 2012 - Sunday, November 11, 2012 Budapest, Hungary

The International Conference on Clinical Practice in Alzheimer Disease (CPAD) aims to bring to families, patients researchers and clinicians the cutting-edge technologies, data and practical lure that are needed in clinical practice. The Conference will focus on the challenges of preventing, diagnosing and managing AD.

We hope to create with your help a meeting that will be interactive with each participant contributing his/her experience in a series of workshops, plenaries and presentations.

Clinical practice is not only our theme but the goal of this exciting new Conference.

Who Should Attend?

Psychiatrists
Neurologists
Researchers in the Alzheimer Field
Nurses
General Practitioners

Main Topics

MCI
Diagnosis
Rare Dementias
Treatment of Depression in Dementia
Treatment of Behavioral Problems in Dementia
National Strategies for Dementia

Clinical Practice in Alzheimer Disease – Conference Secretariat:
Paragon Conventions
Tel: +41 22 5330 948, Fax: +41 22 5802 953
Email: secretariat@cpadconference.com

13th International Fragile X Conference

July 25-29, 2012 Miami, Florida

The National Fragile X Foundation’s biennial international conference is highly regarded and well-known for bringing together families, researchers, doctors, therapists and educators in a setting that is specifically designed to optimize interaction among families and professionals. Increased collaboration between researchers, improved treatment skills of professionals, optimized development of individuals affected by Fragile X and increased understanding and well-being of those impacted by the disorders are the most significant outcomes often sited by previous conference attendees.

The first International Fragile X Conference was a two day event in 1987 held in Denver Colorado with about 150 attendees. Since then it has passed through cities including Albuquerque, Portland, Asheville, Los Angeles, Chicago, Washington DC, Atlanta and Detroit with growing attendance numbers. 2012 will bring the 13th International Fragile X Conference to Miami, FL where we expect over 1,000 attendees.

We present a unique opportunity where researchers and parents can interact throughout the conference. Many a researcher have commented on the experience of socializing with the parents of children with Fragile X, and how the experience has motivated them or reinvigorated their enthusiasm to make a difference in the lives of persons with this disability. The majority of the conference sessions are “Family-Friendly” and cover all three Fragile X conditions (FXS, FXTAS, FXPOI), with the greatest number of sessions focusing on FXS. In addition to the family-friendly sessions there are many scientific and technical sessions. Some of the benefits from attending include:

Discover the latest research by some of the world’s leading Fragile X experts.
Learn new techniques, behavioral interventions and coping strategies.
Connect with researchers clinicians, educators, psychologists and parents.
Get the support you need.
Start a new lifelong friendship and reconnect with old friends.

The objectives of the conference are:

To provide a forum in which professionals from the Fragile X and intellectual disabilities fields can present their scientific, clinical or scholarly work;
To present a general program that will be informative and of interest to all conference participants;
To facilitate the exchange of research, intervention strategies and information relating to all Fragile X-associated Disorders (FXD) including fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI).

Presentation topics will include medical treatments, speech, language and occupational therapies, educational techniques, opportunities for self-determination and independence, genetic counseling strategies and mental health interventions throughout the lifespan.

Based on the ongoing development of new therapies, the conference will include a focus on:

Both pharmacological and non-pharmacological interventions (current and anticipated)
Evaluation tools
Evolving screening and diagnostic technologies

The conference will also highlight basic science presentations on:

The functions of FMRP
The molecular and cellular mechanisms in FXS, FXTAS, and FXPOI
Studies in animal models of FXD

The conference will include a wide variety of other subjects including:

Alternative interventions
Public policy and legislative advocacy
Legal and ethical issues
Sibling issues
Parent to parent support

In addition to presentations from the professional community, parent-led workshops and discussions will also be conducted.

Abstract Topics include:

Academic and Behavioral Interventions and Strategies
ADHD & Disorders of Attention and Impulse Control
Adult Issues and Aging in FXS
Advocacy, Policy Issues: Public and Private Partnerships
Assistive & Augmentative Technology/Computer Enhanced Learning
Autism and FX Studies/Issues/Diagnosis
Clinical Trials of Targeted Treatments
Early Intervention: 0-5 years
Family Dynamics
Financial Planning/Insurance/Grants
FMRP & Molecular/Cellular Studies/Animal Models
FXPOI Clinical Issues
FXTAS: Neuropathology/Non-CNS pathology
FXTAS Caregiving and Clinical Issues
FXTAS/FXPOI Molecular and Cellular Research/Animal Models
Genetic Counseling Issues
Inclusion/Mainstreaming
Molecular Clinical Correlations
Neuroimaging Studies
Neurological and Medical Issues in the Premutation
Neurological and Medical Issues in FXS
Non-traditional Interventions
Occupational Therapy/Sensory Integration
Psychological Therapies and Non-pharmacological Treatment (Behavioral, Cognitive Treatment Trials, etc)
Psychotherapeutic Interventions
Premutation Carrier Studies/Issues and Premutation Clinical Involvement (non-FXTAS)
Prevalence, Screening, Early Diagnosis Strategies & New Testing Technologies
Psychological, Behavioral and Social Studies and Testing in FXS
Psychopharmacologic Treatment of Behavior and Co-morbid Conditions in FXS
Reproductive Options
Self Help Skills: Dental, Eating, Toileting, Other
Service Delivery: Clinic & Non-Clinic based/Rural Outreach/Underserved Populations
Sexuality: Lifespan issues
Special/Unusual/Challenging Cases and Families (lessons learned from these cases)
Speech & Language Studies/Intervention
Targeted Molecular/Cellular Interventions in FXS Models
Treatment Efficacy: Biomarkers/Translational Outcome Measures in FXS
Transitions throughout the Lifespan